ImClone Systems Incorporated’s State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has received approval from the Food and Drug Administration for its state-of-the-art “BB50” manufacturing facility to manufacture multiple products. This approval significantly expands ImClone’s total available production volume capacity for its proprietary pipeline of novel antibodies, which are now entering late-stage clinical development.